Cargando…
Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study
Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVI...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656194/ https://www.ncbi.nlm.nih.gov/pubmed/33192519 http://dx.doi.org/10.3389/fphar.2020.576994 |
_version_ | 1783608331216093184 |
---|---|
author | Zhang, Bo Yu, Yuanhang Hubert, Shawna M. Zhang, Yue Lu, Jianhua Liu, Shihua Xie, Fang Zhao, Liang Lei, Xiao Deng, Wei Chen, Jianying Li, Yunqiao |
author_facet | Zhang, Bo Yu, Yuanhang Hubert, Shawna M. Zhang, Yue Lu, Jianhua Liu, Shihua Xie, Fang Zhao, Liang Lei, Xiao Deng, Wei Chen, Jianying Li, Yunqiao |
author_sort | Zhang, Bo |
collection | PubMed |
description | Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVID-19 are unknown. Methods: A multi-center, retrospective, cross-sectional study, based on five designated tertiary hospitals for the treatment of COVID-19 in Hubei Province, China. 112 cancer patients with COVID-19, and 105 COVID-19 patients without cancer were enrolled in the study between January 1st, 2020 and April 30th, 2020. The risk assessment of pro-inflammatory factors for disease severity and clinical adverse outcomes was identified by univariable and multivariable logistic regression models. Results: Of the 112 cancer patients with COVID-19, 40 (35.7%) patients were in critical condition and 18 (16.1%) patients died unfortunately. Univariate and multivariate analysis demonstrated that hemoglobin level and pro-inflammatory neutrophils and C-reactive protein (CRP), can be used as independent factors affecting the severity of COVID-19; Meanwhile, pro-inflammatory neutrophils and CRP can be used as an independent influencing factor for adverse clinical outcome of death. Moreover, the dynamic changes of neutrophils and CRP were also presented, and compared with COVID-19 patients without cancer, cancer patients with COVID-19 showed higher neutrophil counts and CRP levels. Conclusion: In cancer patients with COVID-19, the significant increase in pro-inflammatory neutrophils and CRP indicated a more critical illness and adverse clinical outcome, and pro-inflammatory neutrophils and CRP played a greater adverse role compare with COVID-19 patients without cancer, which may be the cause of critical illness and adverse clinical outcomes of cancer patients with COVID-19. |
format | Online Article Text |
id | pubmed-7656194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76561942020-11-13 Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study Zhang, Bo Yu, Yuanhang Hubert, Shawna M. Zhang, Yue Lu, Jianhua Liu, Shihua Xie, Fang Zhao, Liang Lei, Xiao Deng, Wei Chen, Jianying Li, Yunqiao Front Pharmacol Pharmacology Background: At present, the epidemic of the novel coronavirus disease 2019 (COVID-19) has quickly engulfed the world. Inflammatory cytokines are associated with the severity and outcomes of patients with COVID-19. However, the prognostic value of pro-inflammatory factors in cancer patients with COVID-19 are unknown. Methods: A multi-center, retrospective, cross-sectional study, based on five designated tertiary hospitals for the treatment of COVID-19 in Hubei Province, China. 112 cancer patients with COVID-19, and 105 COVID-19 patients without cancer were enrolled in the study between January 1st, 2020 and April 30th, 2020. The risk assessment of pro-inflammatory factors for disease severity and clinical adverse outcomes was identified by univariable and multivariable logistic regression models. Results: Of the 112 cancer patients with COVID-19, 40 (35.7%) patients were in critical condition and 18 (16.1%) patients died unfortunately. Univariate and multivariate analysis demonstrated that hemoglobin level and pro-inflammatory neutrophils and C-reactive protein (CRP), can be used as independent factors affecting the severity of COVID-19; Meanwhile, pro-inflammatory neutrophils and CRP can be used as an independent influencing factor for adverse clinical outcome of death. Moreover, the dynamic changes of neutrophils and CRP were also presented, and compared with COVID-19 patients without cancer, cancer patients with COVID-19 showed higher neutrophil counts and CRP levels. Conclusion: In cancer patients with COVID-19, the significant increase in pro-inflammatory neutrophils and CRP indicated a more critical illness and adverse clinical outcome, and pro-inflammatory neutrophils and CRP played a greater adverse role compare with COVID-19 patients without cancer, which may be the cause of critical illness and adverse clinical outcomes of cancer patients with COVID-19. Frontiers Media S.A. 2020-10-22 /pmc/articles/PMC7656194/ /pubmed/33192519 http://dx.doi.org/10.3389/fphar.2020.576994 Text en Copyright © 2020 Zhang, Yu, Herbet, Zhang, Lu, Liu, Xie, Zhao, Lei, Deng, Chen and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhang, Bo Yu, Yuanhang Hubert, Shawna M. Zhang, Yue Lu, Jianhua Liu, Shihua Xie, Fang Zhao, Liang Lei, Xiao Deng, Wei Chen, Jianying Li, Yunqiao Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title | Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title_full | Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title_fullStr | Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title_full_unstemmed | Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title_short | Prognostic Value of Pro-Inflammatory Neutrophils and C-Reactive Protein in Cancer Patient With Coronavirus Disease 2019: A Multi-Center, Retrospective Study |
title_sort | prognostic value of pro-inflammatory neutrophils and c-reactive protein in cancer patient with coronavirus disease 2019: a multi-center, retrospective study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656194/ https://www.ncbi.nlm.nih.gov/pubmed/33192519 http://dx.doi.org/10.3389/fphar.2020.576994 |
work_keys_str_mv | AT zhangbo prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT yuyuanhang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT hubertshawnam prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT zhangyue prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT lujianhua prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT liushihua prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT xiefang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT zhaoliang prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT leixiao prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT dengwei prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT chenjianying prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy AT liyunqiao prognosticvalueofproinflammatoryneutrophilsandcreactiveproteinincancerpatientwithcoronavirusdisease2019amulticenterretrospectivestudy |